"This is not an unfair report and is not biased to favor Novartis in some way."
I agree, whole-heartedly.
Basically, the question Credit Suisse asked was 'if Iclusig is only marginally better would you continue to prescribe Sprycel/Tasigna?' To no great surprise, most answered yes.
The one question I'm most interested in is 'if the 12 month, EPIC MMR is significantly better than the results achieved by Sprycel/Tasigna, would you prescribe Iclusig in a first or second-line setting?' I suspect that question would have a much different result than the one seen in the Credit Suisse survey.
Market Data 
Markets 
AI
